The time has not yet come to remove your chips from the table: Rocket Pharmaceuticals Inc (RCKT)

With 1.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.46 million shares. The 52-week range on RCKT shows that it touched its highest point at $31.47 and its lowest point at $9.33 during that stretch. It currently has a 1-year price target of $43.93. Beta for the stock currently stands at 1.01.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RCKT was up-trending over the past week, with a rise of 3.46%, but this was down by -0.10% over a month. Three-month performance dropped to -23.35% while six-month performance fell -45.92%. The stock lost -63.44% in the past year, while it has lost -16.71% so far this year. A look at the trailing 12-month EPS for RCKT yields -2.75 with Next year EPS estimates of -2.22. For the next quarter, that number is -0.72. This implies an EPS growth rate of 4.47% for this year and 20.51% for next year. EPS is expected to grow by 25.86% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.09%.

Float and Shares Shorts:

At present, 106.34 million RCKT shares are outstanding with a float of 98.64 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RCKT since 8 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.68094 being high and -$2.85835 being low. For RCKT, this leads to a yearly average estimate of -$2.78936.